07.24.2026
FDA Approves Outlook Therapeutics' Lytenava as First Ophthalmic Bevacizumab for Wet AMD
The FDA has approved Outlook Therapeutics' Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD), making it the first FDA-approved ophthalmic formulation of bevacizumab in the United States. According to Outlook, the approval provides retina specialists with an ophthalmic bevacizumab specifically developed for intravitreal use, rather than relying on repackaged formulations originally intended for intravenous administration.